Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 203-209

  Prall, Friedrich ^a   Ostwald, Christiane ^a   Schiffmann, Leif ^a   Barten, Malte ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Colorectal carcinoma; Predictive factor; Repeat polymorphism; Single nucleotide polymorphism; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COLON TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DRUG RESISTANCE; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDYLATE SYNTHASE;

EID: 34548040711     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.203     Document Type: Article

References (19)

1. Moertel CG, Fleming TR, McDonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Int Med 122: 321-326, 1995.
2. Metzger U: Adjuvant therapy for colon and rectal cancer. NIH Consensus Development Conference. Eur J Cancer 26: 753-755, 1990.
3. Longley DB, Harkin P and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003. (Pubitemid 37328853)
4. Popat S, Matakidou A and Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536, 2004. (Pubitemid 41079782)
5. Kaneda S, Nalbantoglu J, Takeishi K, et al: Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem 33: 20277-20284, 1990. (Pubitemid 120014007)
6. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904, 2003. (Pubitemid 36667162)
7. Kawakami K, Salonga D, Park JM, et al: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7: 4096-4101, 2001. (Pubitemid 34044633)
8. Kawakami K and Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004-6007, 2003. (Pubitemid 37187503)
9. + tumor-infiltrating lymphocytes in stage III colorectal carcinomas with and without microsatellite instability. Human Pathol 35: 808-816, 2004.
10. Sobin LH and Wittekind C (eds). TNM Classification of Malignant Tumors. 6th edition. Wiley-Liss, Berlin, 2003.
11. Jass JR, Ajioka Y, Alen JP, et al: Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28: 543-548, 1996.
12. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenom J 1: 65-70, 2001. (Pubitemid 33757985)
13. Park DJ, Stoehlmacher J, Zhang W, et al: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17: 46-49, 2002. (Pubitemid 41398991)
14. Marcuello E, Altes A, Del Rio E, Cesar A, Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112: 733-737, 2004. (Pubitemid 39435256)
15. Uchida K, Hayashi K, Kawakami K, et al: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumour response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 10: 433-439, 2004. (Pubitemid 38173979)
16. Jakobsen A, Nederby Nielsen J, Gyldenkerne N and Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23: 1365-1369, 2005.
17. Iacopetta B, Grieu F, Joseph D and Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827-830, 2001. (Pubitemid 33010548)
18. Tsuji T, Hidaka S, Sawai T, et al: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9: 3700-3704, 2003. (Pubitemid 37169238)
19. Altman DG: Practical Statistics for Medical Research. Chapman & Hall/CRC, Boca Raton, p456, 1991.